Trials / Active Not Recruiting
Active Not RecruitingNCT06304974
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based Chemotherapy
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 497 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion |
| DRUG | Irinotecan | Administration by intravenous infusion |
| DRUG | paclitaxel | Administration by intravenous infusion |
| DRUG | docetaxel | Administration by intravenous infusion |
Timeline
- Start date
- 2024-03-19
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2024-03-12
- Last updated
- 2026-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06304974. Inclusion in this directory is not an endorsement.